CELL STRESS DISCOVERIES LIMITED

Their core work

Cell Stress Discoveries is an Irish biotech SME specializing in cellular stress response mechanisms, particularly the Unfolded Protein Response (UPR) and its role in cancer and neurodegeneration. They translate fundamental research on ER stress pathways — especially IRE1 signaling — into potential therapeutic targets and drug design strategies. Their work spans from understanding how cancer cells hijack stress responses to survive, to investigating how protein misfolding contributes to neurodegenerative diseases, making them a bridge between basic cell biology and translational medicine.

What they specialise in

How they've shifted over time

Their early projects (2017-2018) centered on fundamental ER stress biology — IRE1 signaling, UPR mechanisms, and their links to both cancer and neurodegeneration, with an emphasis on drug design possibilities. By 2019, their focus sharpened toward more translational and disease-specific work: colorectal cancer with specific oncogenic mutations (BRAF), death receptor pathways in tumor immunity, and the role of secretory pathways in neurodegeneration. The shift shows a move from broad mechanistic understanding toward defined therapeutic targets and in vivo disease models.

Moving toward translational applications with in vivo models and specific cancer subtypes, suggesting readiness for preclinical-stage collaborations and industry partnerships in oncology.

How they like to work

Primarily a participant (4 of 5 projects), joining established consortia rather than leading them, though they have coordinated one MSCA Individual Fellowship (UNBRACE). With 38 unique partners across 18 countries, they maintain a broad European network rather than relying on a small circle of repeat collaborators. Their consistent involvement in MSCA training and mobility programs suggests they are valued for specialized expertise contributed to larger research networks.

Broadly connected across Europe with 38 unique consortium partners spanning 18 countries, reflecting the international mobility focus of MSCA programmes. Their network likely includes major academic institutions and research hospitals involved in cancer and neuroscience research.

What sets them apart

As a private SME focused on cell stress biology, they occupy an unusual niche — most UPR and ER stress research sits in academic labs, but Cell Stress Discoveries operates as a company, positioning them to bridge academic discovery and commercial drug development. Their dual expertise in both cancer and neurodegeneration through a shared biological mechanism (UPR/ER stress) means they can contribute to projects in either disease area. For consortium builders, they offer the flexibility of an SME with deep specialist knowledge typically found only in university research groups.

Highlights from their portfolio

• UNBRACE
  Their only coordinated project, focused on an actionable therapeutic target (UPR in BRAF-mutant colorectal cancer) with in vivo patient-derived xenograft models — the most translational of their portfolio.
• DISCOVER
  Addresses tumor immune editing through death receptor signaling (Fas ligand, TRAIL), connecting cell stress biology to the fast-growing immuno-oncology field.
• SAND
  Their longest-running project (2019-2024) and largest single grant (EUR 274,684), expanding their scope into secretory pathway biology and the secretome concept in neurodegeneration.